First Time Loading...

Sonoma Pharmaceuticals Inc
NASDAQ:SNOA

Watchlist Manager
Sonoma Pharmaceuticals Inc Logo
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Watchlist
Price: 0.1574 USD 4.93%
Updated: Apr 23, 2024
Section:
 

Relative Value

SNOA doesn't have a meaningful market cap.

The Relative Value of one SNOA stock under the Base Case scenario is 3.5018 USD. Compared to the current market price of 0.1574 USD, Sonoma Pharmaceuticals Inc is Undervalued by 96%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SNOA Relative Value
Base Case
3.5018 USD
Undervaluation 96%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

0.2
P/S
P/S
Price to Sales
0.2
vs History
95
vs Industry
91
Median 3Y
3.1
Median 5Y
4.5
Industry
2.3
Forward
0.2
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-6.7
Median 5Y
-11
Industry
22.2
Forward
-0.2
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-7.7
Median 5Y
-12
Industry
16.7
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-6.8
Median 5Y
-11.2
Industry
22.6
More Details
0.4
P/B
P/B
Price to Book Value
0.4
vs History
95
vs Industry
77
Median 3Y
4.7
Median 5Y
6.6
Industry
2
More Details
0
EV/S
EV/S
Enterprise Value to Sales
0
vs History
95
vs Industry
93
Median 3Y
2.8
Median 5Y
4.3
Industry
2.5
Forward
0
More Details
0
EV/GP
EV/GP
Enterprise Value to Gross Profit
0
vs History
95
vs Industry
88
Median 3Y
8.3
Median 5Y
9.7
Industry
5
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
56
Median 3Y
-6.4
Median 5Y
-10
Industry
13.2
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
53
Median 3Y
-6.1
Median 5Y
-9.6
Industry
16.5
Forward
-0
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
56
Median 3Y
-7
Median 5Y
-11.5
Industry
15.5
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
43
Median 3Y
-6.9
Median 5Y
-11.4
Industry
17.2
More Details
0
EV/IC
EV/IC
Enterprise Value to IC
0
vs History
95
vs Industry
86
Median 3Y
3.4
Median 5Y
7.1
Industry
1.9
More Details

Multiples Across Competitors

SNOA Competitors Multiples
Sonoma Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
2.5m USD 0.2 -0.5 -0 -0
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
704.9B USD 20.6 134.5 60.6 69.6
DK
Novo Nordisk A/S
CSE:NOVO B
4T DKK 17 47.3 34.6 37.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
361.3B USD 4.4 8.9 11.8 15.6
US
Merck & Co Inc
NYSE:MRK
321.6B USD 5.4 881.2 44 85.8
UK
AstraZeneca PLC
LSE:AZN
174.7B GBP 4.7 36.3 139.3 223.5
CH
Roche Holding AG
SIX:ROG
183.1B CHF 3.1 15.9 8.8 10.4
CH
Novartis AG
SIX:NOVN
182.7B CHF 4.3 13.5 9.9 16.3
US
Pfizer Inc
NYSE:PFE
149.3B USD 2.5 70.3 10.6 15.7
P/E Multiple
Earnings Growth
US
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Average P/E: 151
Negative Multiple: -0.5 		N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
134.5
346%
DK
Novo Nordisk A/S
CSE:NOVO B
47.3
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
8.9
-20%
US
Merck & Co Inc
NYSE:MRK
881.2
7 454%
UK
AstraZeneca PLC
LSE:AZN
36.3
168%
CH
Roche Holding AG
SIX:ROG
15.9
26%
CH
Novartis AG
SIX:NOVN
13.5
15%
US
Pfizer Inc
NYSE:PFE
70.3
680%

See Also

Summary
SNOA intrinsic value, competitors valuation, and company profile.
DCF Valuation
SNOA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SNOA stock valuation using valuation multiples.
Wall Street Estimates
SNOA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SNOA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 130,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.